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Background: Parvovirus B19 presents tropism for human erythroid progenitor cells, causing chronic anemia in
organ transplant recipients, due to their suppressed humoral and cellular responses. Diagnosis may be achieved
through serological tests for detection of anti-B19 antibodies. However, renal transplant recipients are not routinely
tested for parvovirus B19 infection, since there is scanty data or consensus on screening for B19 infection, as well as
for treatment or preventive management of transplanted patients.
Case presentation: Herein we report a kidney transplant recipient, who was unresponsive to treatment of severe
anemia, and presented hypocellular hematopoietic marrow, megaloblastosis and hypoplasia of erythroid lineage
with larger cells with clear nuclei chromatin and eosinophilic nuclear inclusions. This patient was seropositive for
Epstein-Barr and Cytomegalovirus infections and negative for anti-parvovirus B19 IgM and IgG antibodies, although
symptoms were suggestive of parvoviruses infection. A qualitative polymerase chain reaction testing for B19 in
serum sample revealed positive results for B19 virus DNA.
Conclusion: This case report suggests that the diagnostic process for parvovirus B19 in renal transplant recipients
should include a polymerase chain reaction assay to detect B19-DNA, since specific serological tests may be
unreliable given their impaired humoral responses. These results also indicate the importance of considering
parvovirus B19 infection in the differential diagnosis of persistent anemia in transplanted patients.
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The parvovirus (erythrovirus) B19 is a common human
infection worldwide. The clinical manifestations of B19 in-
fection depend on the host’s haematological status and im-
mune responses [1]. In immunocompetent individuals,
B19 causes the erythema infectiosum, also known as “fifth”
disease. Classically, erythema infectiosum affects children
who develop rash, fever and malaise, while in adults it
may be associated with acute symmetrical polyarthropa-
thy. B19 infection during pregnancy is associated with
hydrops fetalis. In patients with chronic haemolytic
anaemia, it correlates with transient aplastic crisis. In* Correspondence: karinabgb@gmail.com
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reproduction in any medium, provided the oraddition, it may also cause chronic anemia and pure red
cell aplasia in immunocompromised patients [1,2].
The cellular receptor for B19 is a globoside (P anti-
gen), present in erythroid precursor cells. The virus
infects, replicates in, and then lyses erythroid progenitor
cells [1]. This direct effect on erythroid cells manifests
characteristically as pure red cell aplasia on bone mar-
row examination, revealing the presence of giant pronor-
moblasts, which can help the diagnostic process. B19
infection depends on mitotically active cells and suscep-
tibility to infection increases in the erythroid precursors
with differentiation [3]. Therefore, tissue distribution of
the blood group P antigen helps to explain the extreme
tropism of B19 for erythroid cells and the effects on
hematopoiesis and bone marrow failure. Patients that do
not present the P antigen in their erythrocytes are,
therefore, resistant to infection by this pathogen [4].
Transmission of B19 infection occurs either by the re-
spiratory route, vertically from mother to fetus, throughtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In immunocompetent patients, B19 infection is charac-
terized by fever, chills and myalgia, which are followed
by rash and joint symptoms [5].These later symptoms are
associated to the appearance of specific antiviral antibodies.
An effective immune response limits intense viremia in
approximately 5 days. B19 specific immunoglobulin M
(IgM) may persist for up to 6 months. Specific IgG is
detectable about 2 weeks following infection and remains
for years. Low reticulocytopenia occurs during viremia, but
hemoglobin levels do not decline. In patients with chronic
hemolytic disorders, transient aplastic crisis may occur
during infection, since reticulocytopenia results in
decreased hemoglobin levels. Nevertheless, the anemia is
transitory resulting from development of specific anti-
bodies against B19 antigens.
In immunocompromised patients, unable to mount
humoral or cellular responses, B19 infection persists and
may cause chronic anemia or erythroid bone marrow
aplasia. Morphologically, bone marrow aspirates show
giant proerythroblasts, large eosinophilic nuclear inclu-
sion bodies, and cytoplasmic vacuolization [6].
Currently, diagnosis is based on detection of B19 IgG
and IgM antibodies or B19 DNA in blood or tissue sam-
ples by polymerase chain reaction (PCR). A simple dot
blot hybridization assay also detects infection; however
the sensitivity of B19 detection is greatly improved by
PCR. Immunohistochemistry is a specific alternative and
may complement diagnosis in cases of placental or fetal
infection [7-9].
Case presentation
This case report describes to a Brazilian woman, 42 years-
old, who presented with a renal failure and was submitted
to haemodialysis for five years, before a kidney transplant,
which occurred in 2007. After transplantation, the thera-
peutic regimen of immunosuppression included prednis-
one (5 mg daily), tacrolimus (5 mg daily) and azathioprine
(50 mg daily). Dosage of serum tacrolimus was 5.8 ng/mL.
The donor’s B19 status for this recipient was un-
known. In December 2010, the patient developed signifi-
cant anemia, which was resistant to erythropoietin
(1,119.0 mUI/mL) and, eventually, required blood trans-
fusion. After transfusion, the patient’s hemoglobin was
6.8 g/dL and her hematocrit was 20.2%.
In April 2011, she presented cutaneous mucosa pale-
ness, fatigue after minimal effort, arthropathy and ma-
laise. She presented at the Hospital Felício Rocho, Belo
Horizonte, MG, Brazil. Levels of hemoglobin and
hematocrit were 3.6 g/dL and 10.3%, respectively. She
received a transfusion of 600 mL of erythrocytes. Reticu-
locyte count was 7,200/mm3, leukocytes 4,100/mm3 and
platelet 220,000/mm3. Dosage of serum creatinine was
2.3 mg/dL, iron (152 mcg/dL), transferrin saturation(89.9%), folate level (20.0 ng/mL), ferritin (938.6 ng/mL)
and vitamin B12 (238.0 pg/mL), which did not suggest a
nutritional or iron deficient anemia. Other laboratory
investigations revealed she was seropositive for anti-
Epstein-Barr (high IgG levels – 477.0 U/mL) and Cyto-
megalovirus (IgG positive) and negative for anti-hepatitis
B, anti-hepatitis C and anti-HIV antibodies.
At this time point, a bone marrow aspirate revealed
hypocellular for red and white cells and platelets. Be-
sides, there were dysplasia and megaloblastosis in the
erythrocytic series, which were attributed to azathioprine
associated with tacrolimus toxicity.
A bone marrow biopsy was also obtained and showed
severe hypoplasia of elements of the erythroid lineage,
presence of larger cells with clear nuclei chromatin and
eosinophilic nuclear inclusions, suggesting inclusions
caused by B19. Nonetheless this evidence has indicated
B19 infection, IgM and IgG assays were negative. How-
ever, as the symptoms and bone marrow biopsy were
suggestive of B19 infection, a qualitative PCR testing for
parvovirus B19 was performed, revealing the presence of
this virus.
The woman received 5 doses of intravenous gamma-
globulin, 400 mg/Kg body weight daily, which improved
the symptoms. A new evaluation revealed an important
increase in hemoglobin, from 3.6 to 12.6 g/dL.Discussion
In transplanted patients, parvovirus B19 infection is
transmitted through the donor organ or contaminated
blood products, during transfusion. Increased suscepti-
bility due to immunosuppressive therapy is likely to
favor establishment of infection [5,10]. B19 is not fre-
quently regarded as a cause of anemia in immunosup-
pressed patients, although anemia without previous
blood loss or reticulocytopenia should alert for potential
B19 infection. Pure red cell aplasia and severe chronic
anemia are also manifestations of B19 infection in organ
transplant recipients and is directly related to the virus
tropism for human erythroid precursor cells. Persistence
of virus in bone marrow leads to prolonged suppression
of erythropoiesis [10-12].
Although many cases of B19 infection in renal trans-
planted patients and various infection-related complica-
tions have been reported, only a few studies have been
performed to evaluate the incidence of active B19 infec-
tion in anemic transplanted patients. Reported inci-
dences of this infection vary from 23 to 31.1% of the
cases. Given the prevalence of B19 infection in the ge-
neral population (approximately 85% of older adults)
and the increased susceptibility of transplanted patients
to viral infection, it may be admitted that B19 infection
is under-reported in this population [11,13-15].
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in definition of infection, in patient selection and in sensi-
tivities of diagnostic methods. The diagnostic tests to
detect anti-B19 IgM antibodies based on μ-capture sand-
wich enzyme immunoassay, display sensitivity of 89.1%
and specificity of 99.4% [16]. The enzyme immunoassay
for detection of IgG antibodies is reported to have a sensi-
tivity of 98.6% and specificity 100% [17]. PCR and real-
time PCR improve the sensitivity of detection of B19
infection, and many clinical laboratories use these molecu-
lar assays to complement the serologic diagnosis. Regar-
ding the sensitivity of molecular methods, the Nested-
PCR results in a thousand fold improved sensitivity when
compared to conventional PCR. Since the qualitative
detection of the DNA is not useful to confirm recent in-
fection, real-Time PCR quantitative assays for viral DNA
may be applied to differentiate acute from chronic infec-
tion [9,18,19]. Therefore, the interpretation of diagnostic
test results is not always straightforward.
Moreover, in immunocompromised patients, false nega-
tive results may occur as due to depressed immune
responses [15]. Egbuna et al. [11] described three trans-
planted patients with inadequate response to recombinant
human erythropoietin treatment, under immunosuppres-
sive therapy. One patient had negative serological tests for
parvovirus B19, but a positive PCR, demonstrating the in-
ability of the patient to mount a detectable effective anti-
viral humoral response. Geetha et al. [12] performed a
review of the literature for relevant articles of parvovirus
B19 related anemia in solid organ transplant recipients,
published between 1974 and 1999. Among the 14 cases
reported, in which both serological and molecular tests
were applied, all of them had positive PCR for B19. How-
ever, the IgM test was negative in two cases; the IgG test
was negative in one and both IgM and IgG were negative
in two cases. In the remaining nine cases, both serological
and molecular tests were positive. Cavallo et al., [13]
described 48 renal transplant recipients with anemia.
Eleven patients (23%) were positive for B19 DNA. How-
ever, ten were seropositive and one seronegative for the
virus.
The case reported herein presented no evidence of
hemolysis, blood loss or nutritional deficiency. The im-
munosuppression consisted of prednisone, azathioprine
and tacrolimus. Persistent anemia and reticulocytopenia
were observed and erythroid aplasia was established,
even with erythropoietin use. Bone marrow biopsy
revealed giant proerythroblasts and intranuclear inclu-
sions, suggesting a chronic B19 infection, which may
have been reactivated because of the immunosuppres-
sion. Furthermore, positive serological tests, i.e. anti-
Epstein-Barr and anti-Cytomegalovirus, which are
commonly seen in B19 disease, were also positive in this
woman.Organ transplant recipients are in risk of symptomatic
B19 virus infections. However, the diagnosis may be
complicated by low titer viremia and the absence of de-
tectable humoral and/or cellular immune response, due
to immunosuppressive therapy [13,15]. In the present
case, despite the evidence of parvovirus B19 infection,
the specific IgM and IgG were negative, requiring a
qualitative B19 PCR in serum, which is more sensitive,
to confirm the diagnostic hypothesis. These serological
findings suggest that B19 infection has been acquired
from the donor of the transplanted kidney and that im-
munosuppression did not allow the development of the
patient’s antibody response. Nevertheless, the hypothesis
of reactivation of B19 infection cannot be ruled out,
since the donor or the patient’s infection status, previ-
ously to the transplant, is unknown.
Transplanted patients are immunossupressed to avoid
host to graft reactions. However, the optimal treatment
for B19 infection requires reduction of intravenous
immunosuppressive drugs and administration of gam-
maglobulin, since immunosuppression may alter host
defense mechanisms, leading to reactivation of the B19
virus or impaired immune responses, when infection is
transmitted through the organ grafting. Although the
B19-associated anemia can improve spontaneously,
intravenous gammaglobulin is usually necessary in the
majority of patients. However, it is still unknown
whether the virus is completely eliminated after this
treatment [12,20].
Conclusion
Parvovirus B19 infection should be considered for the dif-
ferential diagnosis of persistent anemia non responsive to
erythropoietin, aplastic crisis and other opportunist infec-
tions in transplanted patients. The true incidence of this
infection may be underestimated, because B19 serology
may not be routinely searched in transplanted patients.
Since serological tests may fail to detect B19 infection in
immunosuppressed patients, addition of a polymerase
chain reaction assay to detect B19 DNA should be consid-
ered to improve sensitivity and to guide adequate
treatment.
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